NEW YORK, Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form/?id=132337&from=4CLASS PERIOD: November 2, 2022 to Dec ...

Figure 10 Rock sample Sb results over mapped geology at Sherlock Crossing. Latest results are shown as larger squares.(3) Property Map Property Map HIGHLIGHTS Geological and geochemical sampling campaigns designed to guide effective targeting for drill programs in Q2 2025 have been completed at the Tibooburra and John Bull Gold Projects in NSW.Mapping and sampling at both projects will allow for delineation of priority drill targets. Results are pending.At the John Bull Gold Project, 340 soil and 63 ...

NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-for ...

NEW YORK, Feb. 24, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form/?id=131200&from=4CLASS PERIOD: November 2, 2022 to Dece ...

Novo Nordisk (NVO 5.23%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (HIMS -18.50%).This morning, the U.S. Food and Drug Administration (FDA) issued a "declaratory order" confirming the "resolution of shortages of semaglutide injection products ... Ozempic and Wegovy."Novo's good news dayTwo of Novo's biggest money-makers, injectable GLP-1 weight loss drugs Wegovy and Ozempic, have been on the FDA's ...

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form/?id=130530&from=4CLASS PERIOD: November 2, 2022 to Dec ...

Novo Nordisk's share price ( NVO ) (OTCPK: NONOF ) has fallen more than 40% in the past six months, primarily reflecting investor concerns about increased competition in the GLP-1 receptor agonist market, as well as mixed results from aWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, te ...

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-for ...

Pharmaceutical giant Novo Nordisk (NVO -1.22%) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed pretty well, leading to a post-earnings jump in its stock price.Though Novo Nordisk's financial performance was strong, it's worth pointing out several other things management mentioned during its earnings conference call with analysts. Here are two important insights from that call that should excite investors about Novo Nordisk's future.The runaway leader ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NVO -3.62%). The two companies have approved weight loss drugs that are generating billions in revenue, and there's still much more growth on the horizon. Over the past 12 months, however, it's been Eli Lilly that has been the far better buy, rising more than 17%, while Novo Nordisk's stock has fallen by over 30%.But investors shouldn't read too much into this performance as Novo Nordisk just posted a sol ...